Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713205 | 0.86 | EPHX2 (0.45) | EPHX2HRH3CYP2D6KCNH2CHRM1 | |
| SCHEMBL18389809 | 0.78 | CYP1A2 (0.45) | EPHX2CHRM1 | |
| SCHEMBL20154460 | 0.77 | ROCK2 (0.38) | HRH3CYP2D6KCNH2CHRM1 | |
| SCHEMBL8829683 | 0.75 | HPGD (0.43) | MAPK1 | |
| SCHEMBL8829682 | 0.75 | HPGD (0.43) | MAPK1 | |
| SCHEMBL20970531 | 0.74 | CHRM1 (0.43) | CYP2D6CHRM1 | |
| SCHEMBL18704913 | 0.74 | HRH3 (0.46) | EPHX2HRH3CYP2D6KCNH2CHRM1 | |
| SCHEMBL19540884 | 0.74 | HPGD (0.46) | MAPK1 | |
| SCHEMBL19541097 | 0.74 | HPGD (0.46) | MAPK1 | |
| SCHEMBL20353673 | 0.72 | MMP1 (0.38) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | EPHX2 2061/4885MAPK1 52/4885HRH3 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.